Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial

201566 citationsJournal Article

Authors

Ofri Mosenzon

Cheryl Wei · AstraZeneca (Japan)

Jaime A. Davidson · The University of Texas Southwestern Medical Center

Benjamin M. Scirica · Thrombolysis in Myocardial Infarction Study Group

Ilan Yanuv

Aliza Rozenberg

Boaz Hirshberg · AstraZeneca (United States)

Avivit Cahn

Christina Stahre

Abstract

In a large population of older patients with type 2 diabetes, treatment with saxagliptin was not associated with an increased risk of fractures. The association between longer diabetes duration and increased risk of bone fracture is an intriguing finding.

Topics & Keywords

Bone health and osteoporosis research Bone health and treatments Metabolism, Diabetes, and Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Diabetes Care

Volume 38, Issue 11, pp. 2142-2150

DOI: 10.2337/dc15-1068

Field-Weighted Citation Impact: 7.93